Dr. Jain of M.D. Anderson has published an oral abstract in advance of the European Hematological Association Congress June 13-16, 2024:
library.ehaweb.org/eha/2024...
Abstract: S164 Title: COMBINED PIRTOBRUTINIB, VENETOCLAX, AND OBINUTUZUMAB INFIRST-LINE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTICLEUKEMIA (CLL): A PHASE 2 TRIAL
The NCT info page:
clinicaltrials.gov/study/NC...
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
The trial is still recruiting.
The abstract does not mention that ClonoSEQ in peripheral blood was also done at end of Cycles 4 and 9, with similar U-MRD6 (<1 CLL cell in 1 million WBCs) results in the vast majority of patients, according to my trial nurse.
I was one of the first 7 participants, and finished in February, 2024. I have my first followup at the end of May, 2024. We'll be doing ClonoSEQ in peripheral blood again for each quarterly followup, I believe. I did have a single dominant clone detected in bone marrow out of 2.8M cells at end of Cycle 13. I consider that to be U-MRD6 even though it was not 0 detected dominant clones out of the whole sample. It was > 0 <1 out of 1 million.
I had a brief neutropenia. We stopped treatment briefly during cycle 11 in December, 2023 due to an unknown infection with fever > 100.4F/38C. Per the trial protocol, I was admitted to my local hospital, and did IV antibiotics and IVIG. I was discharged after the fever cleared, and then resumed trial meds.
=seymour=